Expression of PD-L1 in triple-negative breast cancer based on different immunohistochemical antibodies

Prognostic Implications of Tumor-Infiltrating Lymphocytes in Association With Programmed Death Ligand 1 Expression in Early-Stage Breast Cancer

(2016) In Hae Park et al.   Clinical Breast Cancer

Programmed death ligand 1 expression in triple-negative breast cancer is associated with tumour-infiltrating lymphocytes and improved outcome

(2016) Rhiannon K Beckers et al.   HISTOPATHOLOGY

Mammary-tumor-educated B cells acquire LAP/TGF-β and PD-L1 expression and suppress anti-tumor immune responses

(2016) Yu Zhang et al.   INTERNATIONAL IMMUNOLOGY

PD-L1 on peripheral blood T lymphocytes is prognostic in patients with non-small cell lung cancer (NSCLC) treated with EGFR inhibitors

(2016) Tarek M. Meniawy et al.   LUNG CANCER

Quantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer

(2016) Joseph McLaughlin et al.   JAMA Oncology

PD-L1 protein expression in breast cancer is rare, enriched in basal-like tumours and associated with infiltrating lymphocytes

(2015) H. R. Ali et al.   ANNALS OF ONCOLOGY

Identification and clinical relevance of PD-L1 expression in primary mucosal malignant melanoma of the head and neck

(2015) Julia Thierauf et al.   MELANOMA RESEARCH

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

(2015) S. P. Patel et al.   MOLECULAR CANCER THERAPEUTICS

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

(2015) Hossein Borghaei et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

(2015) James Larkin et al.   NEW ENGLAND JOURNAL OF MEDICINE

Analysis of Expression of Programmed Cell Death 1 Ligand 1 (PD-L1) in Malignant Pleural Mesothelioma (MPM)

(2015) Susana Cedrés et al.   PLoS One

Unvalidated antibodies and misleading results

(2014) David Rimm et al.   BREAST CANCER RESEARCH AND TREATMENT

PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients

(2014) A D'Incecco et al.   BRITISH JOURNAL OF CANCER

In Situ Tumor PD-L1 mRNA Expression Is Associated with Increased TILs and Better Outcome in Breast Carcinomas

(2014) K. A. Schalper et al.   CLINICAL CANCER RESEARCH

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti-PD-1 Therapy

(2014) J. M. Taube et al.   CLINICAL CANCER RESEARCH

Host Antitumor Immunity Plays a Role in the Survival of Patients With Newly Diagnosed Triple-Negative Breast Cancer

(2014) Sherene Loi   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199

(2014) Sylvia Adams et al.   JOURNAL OF CLINICAL ONCOLOGY

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

(2014) Thomas Powles et al.   NATURE

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

(2014) Roy S. Herbst et al.   NATURE

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

PD-L1 Expression in Triple-Negative Breast Cancer

(2014) E. A. Mittendorf et al.   Cancer Immunology Research

Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular Subtypes

(2013) H. Masuda et al.   CLINICAL CANCER RESEARCH

Clinical impact of programmed cell death ligand 1 expression in colorectal cancer

(2013) Raoul A. Droeser et al.   EUROPEAN JOURNAL OF CANCER

Safety, Efficacy, and Biomarkers of Nivolumab With Vaccine in Ipilimumab-Refractory or -Naive Melanoma

(2013) Jeffrey S. Weber et al.   JOURNAL OF CLINICAL ONCOLOGY

Programmed death ligand-1 expression in non-small cell lung cancer

(2013) Vamsidhar Velcheti et al.   LABORATORY INVESTIGATION

Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer

(2013) A. Prat et al.   ONCOLOGIST

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape

(2012) J. M. Taube et al.   Science Translational Medicine

The prognostic significance of tumor-associated stroma in invasive breast carcinoma

(2012) Soomin Ahn et al.   TUMOR BIOLOGY

Concordance Between Tissue Microarray and Whole-section Estrogen Receptor Expression and Intratumoral Heterogeneity

(2012) H. Evin Gulbahce et al.   APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY

Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies

(2011) Brian D. Lehmann et al.   JOURNAL OF CLINICAL INVESTIGATION

Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates

(2010) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer

(2010) M. Elizabeth H. Hammond et al.   JOURNAL OF CLINICAL ONCOLOGY

High expression of PD-L1 in lung cancer may contribute to poor prognosis and tumor cells immune escape through suppressing tumor infiltrating dendritic cells maturation

(2010) Chuan-Yong Mu et al.   MEDICAL ONCOLOGY

Triple-Negative Breast Cancer: Distinguishing between Basal and Nonbasal Subtypes

(2009) E. A. Rakha et al.   CLINICAL CANCER RESEARCH